EP4087875
Mótlyf fyrir mennskan nýbura Fc viðtaka (FcRn) til meðhöndlunar á blöðrusóttar-röskunum
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
8.1.2021EP published:
28.8.2024EP application number:
21701890.2
EP translation filed:
28.10.2024Grant published:
15.11.2024EPO information:
European Patent Register
Max expiry date:
7.1.2041Expiry date:
7.1.2026Next due date:
31.1.2026
Title in English:
ANTAGONISTS OF HUMAN NEONATAL FC RECEPTOR (FCRN) FOR TREATING PEMPHIGUS DISORDERSLanguage of the patent:
English
Timeline
Today
8.1.2021EP application
28.8.2024EP Publication
28.10.2024Translation submitted
15.11.2024Registration published
7.1.2026Expires
Owner
Name:
Argenx BVAddress:
Industriepark Zwijnaarde 7, 9052 Gent, BE
Inventor
Name:
VERHEESEN, PeterAddress:
9052 Gent, BE
Name:
DUPUY, PatrickAddress:
9052 Gent, BE
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
202062958543 PDate:
8.1.2020Country:
US
Number:
202062960647 PDate:
13.1.2020Country:
US
Classification
Categories:
C07K 16/28, C07K 16/18, A61K 31/573, A61K 39/395, A61P 17/00, A61P 37/06
Annual fees
Number
Paid
Expires
Payer
Number: 5
Paid: 23.1.2025
Expires: 7.1.2026
Payer: CPA Global (Patrafee) AB